NIAID Cooperative Study Group for Autoimmune Disease Prevention (CSGADP)

CSGADP was established in 2001 as a collaborative network of investigators with a focus on halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression with an emphasis on Type 1 diabetes.

Main Areas of Focus

  • To engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease
  • To identify common and disease-specific mechanisms of autoimmunity that can lead to novel pathways and methods to predict autoimmune disease and prevent its development
  • To connect markers of risk for autoimmune disease to alterations in immune function
  • To advance our understanding of genetic and environmental risk for autoimmune disease
  • To foster development of novel tools and approaches to the study of autoimmune disease risk, early pathogenesis, and onset of clinically apparent disease
  • To improve visibility and foster support for understanding early events and pathways toward prevention for systemic autoimmunity
Content last reviewed on